Skip to main content
. 2012 Nov 28;104(1):55–61. doi: 10.1111/cas.12033

Figure 1.

Figure 1

Cytotoxicity of glioma cells induced by proteasome inhibitors. (A) U87 and SF295 cells were treated with the indicated concentration of MG132 for 24 h, and cell viability was measured using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. (B) U87 and SF295 cells were treated with the indicated concentration of MG132 for 24 h, and apoptotic cell death was measured using Annexin V/propidium iodide (PI) double staining followed by flow cytometry. (C) U87 and SF295 cells were treated with the indicated concentration of MG132 for 24 h, and Western blot was performed to measure the level of ubiquitinated proteins. (D) U87 and SF295 cells were treated with 5 μM of MG132 for the indicated time, and cell viability was analyzed using MTT assay. (E) U87 and SF295 cells were treated with vehicle, PSI, epoxomycin (epoxo) or lactacystin (lacta) for 24 h, and cell viability was measured using MTT assay. (F) U87 and SF295 cells were treated with the indicated proteasome inhibitor for 24 h, and apoptotic cell death was measured using flow cytometry. (G) Primary human glioma cells were treated with vehicle or MG132 for 24 h, and cell viability was measured using MTT assay. *P < 0.01.